phase 2_initiation
saveNational Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)
community read0 votes
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Data sources
globaldata
Found something off?
drug timeline · 2
same company · ±60 days · 6
- phase 1 initiationAutologous B7-H3 CAR T: National Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Apr 27, 2026
- phase 2 initiationbusulfan: National Cancer Institute US — busulfan (Phase II Trial Initiation)Apr 27, 2026
- phase 1 2 initiationsacituzumab govitecan: National Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)Apr 27, 2026
- phase 1 completionundisclosed chemotherapy: National Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)Apr 28, 2026
- phase 2 initiation(daratumumab + hyaluronidase (human recombinant)): National Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)Apr 29, 2026
- phase 1 completiontuvusertib: National Cancer Institute US — tuvusertib (Phase I Trial Completion)Apr 30, 2026
related news · 3
🐶 often sniffed alongside
top 8- tagDLBCL6 co-mentions · 3 sources
- tagOncology5 co-mentions · 4 sources
- tagCLL4 co-mentions · 1 sources
- companySandoz Inc2 co-mentions · 1 sources
- tagHematology2 co-mentions · 1 sources
- companyCity of Hope1 co-mentions · 1 sources
- companyNational Cancer Institute US1 co-mentions · 1 sources
- companyGeneral Hospital of the People's Liberation Army1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that